A longitudinal cohort study of mucocutaneous drug eruptions during interferon and ribavirin treatment of hepatitis C

Journal of Clinical Gastroenterology

Volumn 46, Issue 2, 2012, Pages 162-167

  Tavakoli Tabasi, Shahriar ^a,b   Bagree, Ameena ^c  

^a MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF TEXAS   (United States)

Author keywords

drug rash; eczema; hepatitis C; interferon; ribavirin

Indexed keywords

ALPHA INTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ADULT; AFRICAN AMERICAN; APHTHOUS ULCER; ARTICLE; CAUCASIAN; DRUG ERUPTION; DRUG WITHDRAWAL; ECZEMA; FEMALE; FOLLICULITIS; HEPATITIS C; HISPANIC; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LICHEN PLANUS; LOCAL SITE ULCERATION; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MELANOSIS; MIXED INFECTION; MORBILIFORM RASH; MUCOCUTANEOUS DRUG ERUPTION; PITYRIASIS LICHENOIDES; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PRURIGO; PSORIASIFORM ERUPTION; SEBORRHEIC DERMATITIS; TINEA VERSICOLOR; TONGUE DISEASE; TONGUE HYPERMELANOSIS; ULCER; URTICARIA; XEROSIS;

ANTIVIRAL AGENTS; COHORT STUDIES; DRUG ERUPTIONS; DRUG THERAPY, COMBINATION; ECZEMA; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON-ALPHA; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 84855814243     PISSN: 01920790     EISSN: 15392031     Source Type: Journal    
DOI: 10.1097/MCG.0b013e318228b5f6     Document Type: Article

References (24)

1. Alter MJ, Kruszon-Moran D, Nainan OV, et al. The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. N Engl J Med. 1999;341:556-562. (Pubitemid 29384163)
2. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomized trial. Lancet. 2001;358:958-965. (Pubitemid 32913521)
3. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa- 2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med. 2002;347:975-983.
4. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa- 2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med. 1998;339:1485-1492. (Pubitemid 28543496)
5. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl JMed. 1998;339:1493-1499. (Pubitemid 28543497)
6. Dereure O, Raison-Peyron N, Larrey D, et al. Diffuse inflammatory lesions in patients treated with interferon alpha and ribavirin for hepatitis C: a series of 20 patients. Br J Dermatol. 2002;147:1142-1146. (Pubitemid 36963020)
7. Sookoian S, Neglia V, Castano G, et al. High prevalence of cutaneous reactions to interferon alpha plus ribavirin combination therapy in patients with chronic hepatitis C virus. Arch Dermatol. 1999;135:1000-1001. (Pubitemid 29382455)
8. Manjó n-Haces JA, Vá zquez-Ló pez F, Gó mez-Diez S, et al. Adverse cutaneous reactions to interferon alfa-2b plus ribavirin therapy in patients with chronic hepatitis C virus. Acta Dermato-Venereologica. 2001;81:223.
9. Veldt BJ, Schalm SW, Janssen HLA. Severe allergic eczema due to pegylated alpha-Interferon may abate after switching to daily conventional alpha-interferon. J Clin Gastroenterol. 2007; 41:432. (Pubitemid 46573076)
10. Moore M, Elpern D, Carter D. Severe, generalized nummular eczema secondary to interferon alfa-2b plus ribavirin combination therapy in patient with chronic hepatitis C virus infection. Arch Dermatol. 2004;140:215-217. (Pubitemid 38500335)
11. Shen Y, Pielop J, Hsu S. Generalized nummular eczema secondary to peginterferon alfa-2b and ribavirin combination therapy for hepatitis C infection. Arch Dermatol. 2005;141: 102-103. (Pubitemid 40144456)
12. Hanifin J. Atopic dermatitis: puzzles, insights, and progress. Dermatology Focus. 2002;21:11-13.
13. Naldi L, Rebora A. Seborrheic dermatitis. N Engl JMed. 2009; 360:387-396.
14. Beauregard SA, Gilchrest BA. A survey of skin problems and skin care regimens in the elderly. Arch Dermatol. 1987; 123:1638.
15. Gupta AK, Bluhm R, Summerbell R. Pityriasis versicolor. J Eur Acad Dermatol Venereol. 2002;16:19-33. (Pubitemid 34201999)
16. Raslan HM, Ezzat WM, Abd El Hamid MF, et al. Skin manifestations of chronic hepatitis C virus infection in Cairo, Egypt. East Mediterr Health J. 2009;15:692-700.
17. Citro V, Fristachi R, Tarantin G. Extensive psoriasis induced by pegylated interferon: a case report. JMed Case Reports. 2007;1:86.
18. Ohmoto K, Yamamoto S. Angioedema after interferon therapy for chronic hepatitis C. Am J Gastroenterol. 2001;96:1311-1312. (Pubitemid 32319194)
19. Willems M, Munte K, Vrolijk JM, et al. Hyperpigmentation during interferon-alpha therapy for chronic hepatitis C virus infection. Br J Dermatol. 2003;149:90-394.
20. Gurguta C, Kauer C, Bergholz U, et al. Tongue and skin hyperpigmentation during PEG-interferon-alpha/ribavirin therapy in dark-skinned non-Caucasian patients with chronic hepatitis C. Am J Gastroenterol. 2006;101:197-198. (Pubitemid 43381730)
21. Torres HA, Bull L, Arduino RC, et al. Tongue hyperpigmentation in a Caucasian patient coinfected with HIV and hepatitis C during peginterferon alfa-2b and ribavirin therapy. Am J Gastroenterol. 2007;102:1334-1335. (Pubitemid 46802016)
22. Dalekos GN, Christodoulou D, Kistis KG, et al. A prospective evaluation of dermatological side-effects during alpha-interferon therapy for chronic viral hepatitis. Eur J Gastroenterol Hepatol. 1998;10:933-939. (Pubitemid 28561287)
23. Dlova NC, Mosam A. Inflammatory noninfectious dermatoses of HIV. Derematol Clin. 2006;24:439-448. (Pubitemid 44436791)
24. Reddy KR, Wright TL, Pockros PJ, et al. Efficacy and safety of pegylated (40-kd) interferon alpha-2a compared with interferon alpha-2a in noncirrhotic patients with chronic hepatitis C. Hepatology. 2001;33:433-438.(Pubitemid 32119033)